Management options for Takayasu arteritis

Expert Opinion on Orphan Drugs

Volumn 1, Issue 9, 2013, Pages 685-693

  Tombetti, Enrico ^a   Manfredi, Angelo ^a   Sabbadini, Maria Grazia ^a   Baldissera, Elena ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Angioplasty; Medical therapy; Surgery; Takayasu arteritis; TNF inhibitors

Indexed keywords

ABATACEPT; ACETYLSALICYLIC ACID; ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; GOLIMUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; TOCILIZUMAB;

ADVERSE DRUG REACTION; AORTA ARCH SYNDROME; ATHEROSCLEROSIS; CARDIOVASCULAR MORTALITY; CLINICAL FEATURE; CORTICOSTEROID THERAPY; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REVIEW; THERAPY EFFECT;

EID: 84896734459     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2013.827570     Document Type: Review

References (89)

1. Kerr GS. Takayasu arteritis. Ann Intern Med 1994;120(11):919-29
2. Mason JC. Takayasu arteritis-advances in diagnosis and management. Nat Rev Rheumatol 2010;6(7):406-15
3. Ogino H, et al. Overview of late outcome of medical and surgical treatment for Takayasu arteritis. Circulation 2008;118(25):2738-47
4. Maksimowicz-McKinnon K, Clark et al. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 2007;56(3):1000-9
5. Freitas DS, et al. Takayasu arteritis: assessment of response to medical therapy based on clinical activity criteria and imaging techniques. Rheumatol Int 2012;32(3):703-9
6. Hotchi M. Pathological studies on Takayasu arteritis. Heart Vessels Suppl 1992;7:11-17
7. Seko Y, et al. Perforin-secreting killer cell infiltration and expression of a 65-kD heat-shock protein in aortic tissue of patients with Takayasu's arteritis. J Clin Invest 1994;93(2):750-8
8. Weyand CM, et al. Medium- and large-vessel vasculitis. N Engl J Med 2003;349(2):160-9
9. Mwipatayi BP, et al. Takayasu arteritis: clinical features and management: report of 272 cases. ANZ J Surg 2005;75(3):110-17
10. Subramanyan R, Joy J, Balakrishnan KG. Natural history of aortoarteritis (Takayasu's disease). Circulation 1989;80(3):429-37
11. Ishikawa K, Maetani S. Long-term outcome for 120 Japanese patients with Takayasu's disease. Clinical and statistical analyses of related prognostic factors. Circulation 1994;90(4):1855-60
12. Sharma BK, et al. Takayasu arteritis in India. Heart Vessels Suppl 1992;7:37-43
13. Park M.C, et al. Clinical characteristics and outcomes of Takayasu's arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification. Scand J Rheumatol 2005;34(4):284-92
14. Maksimowicz-McKinnon K, Hoffman GS. Takayasu arteritis: what is the long-term prognosis? Rheum Dis Clin North Am 2007;33(4):777-86, vi
15. Cong X.L, et al. Takayasu's arteritis: clinical features and outcomes of 125 patients in China. Clin Rheumatol 2010;29(9):973-81
16. Lee G.Y, et al. Cardiovascular manifestations of Takayasu arteritis and their relationship to the disease activity: analysis of 204 Korean patients at a single center. Int J Cardiol 2012;159(1):14-20
17. Soto M.E, et al. Takayasu arteritis: clinical features in 110 Mexican Mestizo patients and cardiovascular impact on survival and prognosis. Clin Exp Rheumatol 2008;26(3 Suppl 49):S9-15
18. Arnaud L. et al. Takayasu arteritis in France: a single-center retrospective study of 82 cases comparing white, North African, and black patients. Medicine (Baltimore) 2010;89(1):1-17
19. Manfredi A.A, et al. Pentraxins, humoral innate immunity and tissue injury. Curr Opin Immunol 2008;20(5):538-44
20. Baldini M, et al. Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemia. Arthritis Rheum 2012;64(3):854-65
21. Dagna L, et al. Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med 2011;155(7):425-33
22. Willis M.S, et al. Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease. Circ Res 2010;106(3):463-78
23. Maugeri N, et al. Platelet-leukocyte deregulated interactions foster sterile inflammation and tissue damage in immune-mediated vessel diseases. Thromb Res 2012;129(3):267-73
24. Mavrogeni S, et al. The role of multimodality imaging in the evaluation of Takayasu arteritis. Semin Arthritis Rheum 2013;42(4):401-12
25. Mukhtyar C, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009;68(3):318-23
26. Ishikawa K. Effects of prednisolone therapy on arterial angiographic features in Takayasu's disease. Am J Cardiol 1991;68(4):410-13
27. Vanoli M, et al. Takayasu's arteritis: a study of 104 Italian patients. Arthritis Rheum 2005;53(1):100-7
28. Bicakcigil M, et al. Takayasu's arteritis in Turkey - clinical and angiographic features of 248 patients. Clin Exp Rheumatol 2009;27(1 Suppl 52):S59-64
29. Hoffman G.S, et al. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994;37(4):578-82
30. Valsakumar A.K, et al. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. J Rheumatol 2003;30(8):1793-8
31. Shinjo SK, et al. Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clin Rheumatol 2007;26(11):1871-5
32. Daina E A, et al. Remuzzi, Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. Ann Intern Med 1999;130(5):422-6
33. Shelhamer JH, et al. Takayasu's arteritis and its therapy. Ann Intern Med 1985;103(1):121-6
34. de Souza AW, et al. Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. Scand J Rheumatol 2012;41(3):227-30
35. Horigome H, Kamoda T, Matsui A. Treatment of glucocorticoid-dependent Takayasu's arteritis with cyclosporin. Med J Aust 1999;170(11):566
36. Matsuyama A, et al. Minocycline for the treatment of Takayasu arteritis. Ann Intern Med 2005;143(5):394-5
37. Park MC, et al. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford) 2006;45(5):545-8
38. Hoffman GS, et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004;50(7):2296-304
39. Molloy ES, et al. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 2008;67(11):1567-9
40. Schmidt J, et al. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup. Arthritis Care Res (Hoboken) 2012;64(7):1079-83
41. Mekinian A, et al. Efficacy and tolerance of infliximab in refractory Takayasu arteritis: french multicentre study. Rheumatology (Oxford) 2012;51(5):882-6
42. Quartuccio L, et al. Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab. Clin Exp Rheumatol 2012;30(6):922-8
43. Comarmond C, et al. Anti TNF-alpha in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmun Rev 2012;11(9):678-84
44. Noris M, et al. Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation 1999;100(1):55-60
45. Seitz M, et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011;141:w13156
46. Salvarani C, et al. Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-alpha blockers. Clin Exp Rheumatol 2012;30(1 Suppl 70):S90-3
47. Unizony S, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken) 2012;64(11):1720-9
48. Salvarani C, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 2012;51(1):151-6
49. Bredemeier M, et al. One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab. Clin Exp Rheumatol 2012;30(1 Suppl 70):S98-100
50. Xenitidis T, et al. Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis. Rheumatology (Oxford) 2013
51. Tombetti et al. Treatment of refractory Takayasu arteritis with tocilizumab: seven Italian patients from a single referral Center. J Rheumatology 2013; 40(12): doi:10.3899/jrheum.130536
52. Hoyer BF, et al. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 2012;71(1):75-9
53. Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis. ClinicalTrials.gov: NCT00556439
54. Seyahi E, et al. Aortic and coronary calcifications in Takayasu arteritis. Semin Arthritis Rheum 2013
55. Seyahi E, et al. Atherosclerosis in Takayasu arteritis. Ann Rheum Dis 2006;65(9):1202-7
56. de Souza AW, et al. Antiplatelet therapy for the prevention of arterial ischemic events in takayasu arteritis. Circ J 2010;74(6):1236-41
57. Nesher G, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004;50(4):1332-7
58. Maugeri N, et al. Leukocyte and platelet activation in patients with giant cell arteritis and polymyalgia rheumatica: a clue to thromboembolic risks? Autoimmunity 2009;42(4):386-8
59. Hoes JN, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007;66(12):1560-7
60. Grossman JM, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010;62(11):1515-26
61. van Assen S, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011;70(3):414-22
62. Bijl M, et al. Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmun Rev 2012;11(8):572-6
63. Maugeri N, et al. Translational mini-review series on immunology of vascular disease: mechanisms of vascular inflammation and remodelling in systemic vasculitis. Clin Exp Immunol 2009;156(3):395-404
64. Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol 2005;17(1):16-24
65. Tyagi S, et al. Early and long-term results of subclavian angioplasty in aortoarteritis (Takayasu disease): comparison with atherosclerosis. Cardiovasc Intervent Radiol 1998;21(3):219-24
66. Tyagi S, et al. A decade of subclavian angioplasty: aortoarteritis versus atherosclerosis. Indian Heart J 1996;48(6):667-71
67. Joseph S, et al. Percutaneous transluminal angioplasty of the subclavian artery in nonspecific aortoarteritis: results of long-term follow-up. J Vasc Interv Radiol 1994;5(4):573-80
68. Sharma S, et al. Renal artery stenosis caused by nonspecific arteritis (Takayasu disease): results of treatment with percutaneous transluminal angioplasty. AJR Am J Roentgenol 1992;158(2):417-22
69. Sharma S, et al. Results of renal angioplasty in nonspecific aortoarteritis (Takayasu disease). J Vasc Interv Radiol 1998;9(3):429-35
70. Lee BB, et al. Endovascular management of takayasu arteritis: is it a durable option? Vascular 2009;17(3):138-46
71. Liang P, Tan-Ong M, Hoffman GS. Takayasu's arteritis: vascular interventions and outcomes. J Rheumatol 2004;31(1):102-6
72. Park MC, et al. Post-interventional immunosuppressive treatment and vascular restenosis in Takayasu's arteritis. Rheumatology (Oxford) 2006;45(5):600-5
73. Saadoun D, et al. Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience. Circulation 2012;125(6):813-19
74. Avery RK. Cardiac-allograft vasculopathy. N Engl J Med 2003;349(9):829-30
75. Mancini D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003;108(1):48-53
76. Eisen HJ, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349(9):847-58
77. Nordmann AJ, et al. Clinical outcomes of stents versus balloon angioplasty in non-acute coronary artery disease. A meta-analysis of randomized controlled trials. Eur Heart J 2004;25(1):69-80
78. Sharma BK, et al. A follow-up study of balloon angioplasty and de-novo stenting in Takayasu arteritis. Int J Cardiol 2000;75(Suppl 1):S147-52
79. Stone GW, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356(10):998-1008
80. Qureshi MAZ, Martin RK. Greenberg, Endovascular management of patients with Takayasu arteritis: stents versus stent grafts. Semin Vasc Surg 2011;24(1):44-52
81. Miyata T, et al. Long-term survival after surgical treatment of patients with Takayasu's arteritis. Circulation 2003;108(12):1474-80
82. Weaver FA, Yellin AE. Surgical treatment of Takayasu arteritis. Heart Vessels Suppl 1992;7:154-8
83. Weaver FA, et al. Renal revascularization in Takayasu arteritis-induced renal artery stenosis. J Vasc Surg 2004;39(4):749-57
84. Kim YW, et al. Surgical bypass vs endovascular treatment for patients with supra-aortic arterial occlusive disease due to Takayasu arteritis. J Vasc Surg 2012;55(3):693-700
85. Fields CE, et al. Takayasu's arteritis: operative results and influence of disease activity. J Vasc Surg 2006;43(1):64-71
86. Pajari R, Hekali P, Harjola PT. Treatment of Takayasu's arteritis: an analysis of 29 operated patients. Thorac Cardiovasc Surg 1986;34(3):176-81
87. Feng R, et al. Aortorenal bypass with autologous saphenous vein in Takayasu arteritis-induced renal artery stenosis. Eur J Vasc Endovasc Surg 2011;42(1):47-53
88. Miyata T, et al. Anastomotic aneurysms after surgical treatment of Takayasu's arteritis: a 40-year experience. J Vasc Surg 1998;27(3):438-45
89. Erdogan A, et al. PTFE patching to prevent anastomotic aneurysm formation in Takayasu's arteritis. Eur J Vasc Endovasc Surg 2003;25(5):478-80